Logo
  • Home
  • AI Agent
  • Annotations
  • Watchlists
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy

  • Get the full experience

    We save the real magic for signed-in users.

Charles River Laboratories International, Inc.(CRL US)

$345.37+5.711.68%Ext:$348.72+3.350.97%(Market Closed · 00:00:05 UTC)

Overview

ProfileEntity Structure

Documents

SEC Filings
CategorizedChronologicalBy Owner

Financials & Metrics

FinancialsChartingShort InterestEmployees
Logo
CRL US​

SEC Filings

Financials(110)

Expand
  • 10-QQ2ended 27 Jun 20265 Aug
  • 10-QQ1ended 28 Mar 20267 May
  • 10-KFY 2025ended 27 Dec 202518 Feb
  • 10-QQ3ended 27 Sept 20255 Nov 2025
  • 10-QQ2ended 28 Jun 20256 Aug 2025
  • 10-QQ1ended 29 Mar 20257 May 2025
  • 10-KFY 2024ended 28 Dec 202419 Feb 2025
  • 10-QQ3ended 28 Sept 20246 Nov 2024
  • 10-QQ2ended 29 Jun 20247 Aug 2024
  • 10-QQ1ended 30 Mar 20249 May 2024
  • 10-KFY 2023ended 30 Dec 202314 Feb 2024
  • 10-QQ3ended 30 Sept 20238 Nov 2023
  • 10-QQ2ended 1 Jul 20239 Aug 2023
  • 10-QQ1ended 1 Apr 202311 May 2023
  • 10-QQ3ended 24 Sept 20222 Nov 2022

Events(240)

Expand
  • 8-K1 NEWS RELEASE CHARLES RIVER HIGHLIGHTS REFRESHED STRATEGIC VISION TO DRIVE PROFITABLE GROWTH AND LONG-TERM VALUE CREATION AT 2026 INVESTOR DAY – Outlines Pathway to Purpose Strategy to Modernize the Company, Strengthen Its Scientific Portfolio, and Enhance the Client Experience – – Issues Long-Term Financial Targets through 2030 – – Reaffirms 2026 Financial Guidance with Revenue and Non-GAAP Earnings per Share Expected at the Upper Ends of Prior Ranges – WILMINGTON, MA, September 24, 2026 – Charles River Laboratories International, Inc. (NYSE: CRL) will host its 2026 Investor Day today, September 24, 2026, starting at 9:00 a.m. ET. Birgit Girshick, Chief Executive Officer, along with members of the senior management team, will highlight a refreshed strategic vision, Pathway to Purpose, to modernize the Company, strengthen its scientific portfolio, and drive profitable growth to enhance long-term shareholder value creation. Ms. Girshick said, “Our Pathway to Purpose strategy is designed to strengthen Charles River's position as a leading scientific partner to the biopharmaceutical industry. As innovation across drug development accelerates, we believe there are significant opportunities to leverage our scientific expertise, operational excellence, and client-centric approach to drive scalable, profitable growth and to lead the future of drug development.” Pathway to Purpose is centered on three strategic initiatives: • Modernizing the Company to Drive Greater Productivity and Efficiency: Through its recently introduced Create the Future™ program, Charles River expects to generate over $300 million in cumulative savings from 2027 through 2030 by simplifying processes and increasing automation and digital enablement. The Company will expand its use of AI-assisted digital tools to improve operating efficiency, reduce drug development timelines, and enhance client satisfaction.2 • Strengthening a World-Class Scientific Portfolio: Charles River will expand its innovative scientific capabilities through organic and inorganic investments. Priority investment areas include bioanalysis, in vitro testing, and related scientific solutions. Charles River expects its bioanalysis revenue to grow organically at a high-single-digit CAGR to approximately $450 million in 2030. • Delivering a Customized, Client-Centric Approach: The Company’s client-centric approach will further enable it to capitalize on improving biopharmaceutical R&D demand, growth in biologics and complex modalities, the potential benefit of AI-assisted drug discovery, and the increasing complexity of scientific research. Charles River is expanding its Apollo™ cloud-based platform to create a more seamless client experience. Apollo™ now serves more than 18,000 client users through its scientific decision-support and e-commerce capabilities and was recently expanded to support Manufacturing Solutions’ clients. Through these initiatives and disciplined capital deployment, the Company intends to reinforce its leadership position in early-stage drug development with comprehensive regulated testing capabilities across the R&D continuum. Financial Targets In conjunction with Investor Day, the Company is reaffirming its 2026 financial guidance, which was last updated on August 5, 2026. The Company now expects revenue and non-GAAP earnings per share to be at the upper ends of their respective guidance ranges, primarily reflecting continued favorable demand from biopharmaceutical clients. The Company is also introducing the following long-term financial targets through 2030: 2026 GUIDANCE(1) 2030 TARGET(2) Revenue growth, organic (3) Upper end of 0% – 1% growth 5% – 7% 2027-2030 CAGR Non-GAAP operating margin (4) 21.0% – 21.3% ~24% Non-GAAP EPS estimate (4) Upper end of $11.15 – $11.45 Low-double-digit 2027-2030 CAGR3 Footnotes: (1) The reconciliations of GAAP to non-GAAP financial information for 2026 guidance, which were last updated on August 5, 2026, can be found on the Investor Relations section of the Company’s website at ir.criver.com. (2) Financial targets through 2030 do not include the impact of future acquisitions or divestitures. The financial targets are not projections and do not constitute financial guidance; they are subject to significant uncertainties and contingencies and are based upon management's current assumptions, which are subject to change. (3) Organic growth (non-GAAP) is defined as reported revenue growth adjusted for completed acquisitions, divestitures, and foreign currency translation. (4) Non-GAAP operating margin and earnings per share primarily excludes: (i) acquisition-related amortization; (ii) costs related to the evaluation and integration of acquisitions and divestitures; (iii) costs related to the Create the Future™ transformation program including site consolidation, severance, impairment, third-party consulting and professional services; and other costs related to restructuring actions and efficiency initiatives; and (iv) certain venture capital and other strategic investment losses/(gains), net, as well as certain other costs. Investor Day Webcast Details A link to the live webcast and presentation materials for Charles River’s 2026 Investor Day will be available at ir.criver.com shortly before the event begins. A replay of the webcast will be available on the same website following the conclusion of the event. Use of Non-GAAP Financial Measures This press release contains forward-looking, non-GAAP financial measures: organic revenue growth, non-GAAP operating margin, and non-GAAP earnings per share. We do not reconcile forward-looking non-GAAP measures to the comparable GAAP measures because of the inherent difficulty in predicting and estimating the future impact and timing of foreign currency translation, acquisitions, divestitures, and any other potential adjustments which would be reflected in any forecasted GAAP measure. There are limitations in using non-GAAP financial measures, as they are not presented in accordance with generally accepted accounting principles, and may be different than non-GAAP financial measures used by other companies. In particular, we believe that the inclusion of supplementary non-GAAP financial measures in this press release helps investors to gain a meaningful understanding of our core operating results and future prospects without the effect of these often-one-time charges and is consistent with how management measures and forecasts the Company's performance, especially when comparing such results to prior periods or forecasts. We believe that the financial impact of our acquisitions and divestitures (and in certain cases, the evaluation of such acquisitions and divestitures, whether ultimately consummated) is often large relative to our overall financial performance, which can adversely affect the comparability of our results on a period-to-period basis. In addition, certain activities and their underlying associated costs, such as business acquisitions, generally occur periodically but on an unpredictable basis. Non-GAAP results also allow investors to compare the Company’s operations against the financial results of other companies in the industry who similarly provide non-GAAP results. The non-GAAP financial measures included in this press release are not meant to be considered4 superior to or a substitute for results of operations presented in accordance with GAAP. The Company intends to continue to assess the potential value of reporting non-GAAP results consistent with applicable rules and regulations. Caution Concerning Forward-Looking Statements This press release includes forward-looking statements within the meaning of the federal securities laws. Forward-looking statements may be identified by the use of words such as “anticipate,” “believe,” “expect,” “intend,” “will,” “would,” “may,” “estimate,” “plan,” “outlook,” and “project,” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These statements also include statements regarding: the Company’s plans or prospects, expectations and long-term goals associated with our business; the Company's expectations concerning future financial and operating performance, including the Company's commitment to, and ability to create long-term value for shareholders and to successfully execute on the strategies described herein. Forward-looking statements are based on Charles River’s current expectations and beliefs, and involve a number of risks and uncertainties that are difficult to predict and that could cause actual results to differ materially from those stated or implied by the forward-looking statements. Those risks and uncertainties include, but are not limited to, the ability to execute on, the results, and the impact of the Company’s Pathway to Purpose strategy and related initiatives. Furthermore, these and other risks relating to the Company are set forth in the documents filed by Charles River with the Securities and Exchange Commission, including without limitation, the Risk Factors in the Company’s Annual Report on Form 10-K filed February 18, 2026, as well as the Company’s other filings with the Securities and Exchange Commission. Because forward- looking statements involve risks and uncertainties, actual results and events may differ materially from results and events currently expected by Charles River, and Charles River assumes no obligation and expressly disclaims any duty to update information contained in this press release except as required by law. About Charles River Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies, and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development, and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com. # # #5 Investor Contact: Media Contact: Todd Spencer Amy Cianciaruso Corporate Vice President, Corporate Senior Vice President, Investor Relations Chief Communications Officer 781.222.6455 781.222.6168 [email protected] [email protected]24 Sep
  • 8-KResults of Operations and Financial Condition5 Aug
  • 8-KDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers11 May
  • 8-KResults of Operations and Financial Condition7 May
  • 8-KRegulation FD Disclosure25 Feb
  • 8-KDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers18 Feb
  • 8-KResults of Operations and Financial Condition18 Feb
  • 8-KResults of Operations and Financial Condition13 Jan
  • 8-KDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers9 Jan
  • 8-KRegulation FD Disclosure3 Dec 2025
  • 8-KOther Events17 Nov 2025
  • 8-KResults of Operations and Financial Condition5 Nov 2025
  • 8-K/ADirector/Officer Changes & Compensatory Arrangements19 Sep 2025
  • 8-KDirector/Officer Changes & Compensatory Arrangements16 Sep 2025
  • 8-KResults of Operations and Financial Condition6 Aug 2025

Insider Ownership(1.7K)

Expand
  • 4Parisotto Shannon M23 Oct
  • 4Statement of changes in beneficial ownership7 Oct
  • 4Coleman Glenn2 Oct
  • 4FOSTER JAMES C27 Aug
  • 4Girshick Birgit20 Aug
  • 4Parisotto Shannon M20 Aug
  • 4Andrews Nancy C20 Aug
  • 4Girshick Birgit13 Aug
  • 4Parisotto Shannon M13 Aug
  • 4LaPlume Joseph W11 Aug
  • 4FOSTER JAMES C11 Aug
  • 4Knell Michael Gunnar10 Aug
  • 4Creamer Victoria L10 Aug
  • 4Parisotto Shannon M6 Aug
  • 4FOSTER JAMES C1 Jul

Beneficial Ownership(140)

Expand
  • SC 13G/ACHARLES RIVER LABORATORIES INTERNATIONAL, INC.8 Sep
  • SC 13GCHARLES RIVER LABORATORIES INTERNATIONAL, INC.13 Aug
  • SC 13G/ACHARLES RIVER LABORATORIES INTERNATIONAL, INC.6 Aug
  • SC 13G/ACHARLES RIVER LABORATORIES INTERNATIONAL, INC.6 May
  • SC 13GCHARLES RIVER LABORATORIES INTERNATIONAL, INC.6 May
  • SC 13GCHARLES RIVER LABORATORIES INTERNATIONAL, INC.29 Apr
  • SC 13G/ACHARLES RIVER LABORATORIES INTERNATIONAL, INC.26 Mar
  • SC 13GCHARLES RIVER LABORATORIES INTERNATIONAL, INC.12 Feb
  • SC 13G/ACHARLES RIVER LABORATORIES INTERNATIONAL, INC.10 Feb
  • SC 13G/ACHARLES RIVER LABORATORIES INTERNATIONAL, INC.14 Nov 2025
  • SC 13G/ACHARLES RIVER LABORATORIES INTERNATIONAL, INC.12 Nov 2025
  • SC 13GCHARLES RIVER LABORATORIES INTERNATIONAL, INC.14 Aug 2025
  • SC 13G/ACHARLES RIVER LABORATORIES INTERNATIONAL, INC.12 May 2025
  • SC 13G/ACHARLES RIVER LABORATORIES INTERNATIONAL, INC.17 Apr 2025
  • SC 13G/ACHARLES RIVER LABORATORIES INTERNATIONAL, INC.8 Nov 2024

Other Ownership(43)

Expand
  • 144FOSTER JAMES C22 Oct
  • 144Parisotto Shannon M21 Oct
  • 144Parisotto Shannon M5 Oct
  • 144FOSTER JAMES C25 Aug
  • 144Parisotto Shannon M19 Aug
  • 144Andrews Nancy C18 Aug
  • 144Parisotto Shannon M11 Aug
  • 144Girshick Birgit11 Aug
  • 144FOSTER JAMES C10 Aug
  • 144Knell Michael Gunnar6 Aug
  • 144Creamer Victoria L6 Aug
  • 144Parisotto Shannon M5 Aug
  • 144FOSTER JAMES C29 Jun
  • 144LaPlume Joseph W22 Aug 2025
  • 144WALLMAN RICHARD F18 Aug 2025

Proxies(88)

Expand
  • ARSAnnual report to security holders31 Mar
  • DEF 14ADefinitive proxy statement31 Mar
  • DEF 14ADefinitive proxy statement2 Apr 2025
  • ARSAnnual report to security holders2 Apr 2025
  • DEFA14ADefinitive additional materials24 Apr 2024
  • DEFA14ADefinitive additional materials1 May 2023
  • ARSAnnual report to security holders30 Mar 2023
  • DEF 14ADefinitive proxy statement30 Mar 2023
  • DEFA14ADefinitive additional materials25 Apr 2022
  • DEF 14ADefinitive proxy statement30 Mar 2022
  • DEF 14ADefinitive proxy statement26 Mar 2021
  • DEF 14ADefinitive proxy statement26 Mar 2020
  • DEF 14ADefinitive proxy statement4 Apr 2019
  • DEF 14ADefinitive proxy statement29 Mar 2018
  • DEF 14ADefinitive proxy statement30 Mar 2017

Registrations(113)

Expand
  • S-8Registration statement (employee benefit plan)7 May
  • S-3ASRAutomatic shelf registration statement (S-3)9 May 2024
  • S-3ASRAutomatic shelf registration statement (S-3)4 May 2021
  • S-8Registration statement (employee benefit plan)21 May 2020
  • S-8Registration statement (employee benefit plan)18 May 2018
  • S-3ASRAutomatic shelf registration statement (S-3)9 May 2018
  • S-8Registration statement (employee benefit plan)13 Jul 2016
  • S-3ASRAutomatic shelf registration statement (S-3)30 Jul 2015
  • S-8Registration statement (employee benefit plan)1 Aug 2013
  • S-3ASRAutomatic shelf registration statement (S-3)31 Jul 2012
  • S-8Registration statement (employee benefit plan)17 Jun 2011
  • S-3ASRAutomatic shelf registration statement (S-3)4 Aug 2009
  • S-8Registration statement (employee benefit plan)4 Aug 2009
  • 424B7Prospectus filing (Rule 424(b)(7))17 Sep 2007
  • 424B7Prospectus filing (Rule 424(b)(7))16 Jul 2007

Filing Review Correspondence(11)

Expand
  • CORRESPFiling review correspondence21 Nov 2023
  • CORRESPFiling review correspondence17 Dec 2020
  • CORRESPFiling review correspondence9 Dec 2015
  • CORRESPFiling review correspondence2 Dec 2010
  • CORRESPFiling review correspondence17 Nov 2010
  • UPLOADFiling review upload5 Nov 2010
  • UPLOADFiling review upload1 Oct 2010
  • CORRESPFiling review correspondence30 Sep 2010
  • CORRESPFiling review correspondence30 Sep 2010
  • CORRESPFiling review correspondence30 Jun 2006
  • UPLOADFiling review upload16 Jun 2006

Other(13)

Expand
  • SDSD8 May
  • SDSD16 May 2025
  • SDSD29 May 2024
  • SDSD25 May 2023
  • SDSD26 May 2022
  • SDSD28 May 2021
  • SDSD28 May 2020
  • SDSD30 May 2019
  • SDSD31 May 2018
  • SDSD31 May 2017
  • SDSD31 May 2016
  • SDSD27 May 2015
  • SDSD30 May 2014